Literature DB >> 29057102

Prof. Yun Fan: persistence guarantees expertise, patience conquers difficulties.

Kai-Ping Zhang, Li Ma.   

Abstract

Year:  2017        PMID： 29057102      PMCID： PMC5633798          DOI： 10.21037/jtd.2017.09.144

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  3 in total

1.  Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.

Authors:  Jin-Ji Yang; Caicun Zhou; Yisheng Huang; Jifeng Feng; Sun Lu; Yong Song; Cheng Huang; Gang Wu; Li Zhang; Ying Cheng; Chengping Hu; Gongyan Chen; Li Zhang; Xiaoqing Liu; Hong Hong Yan; Fen Lai Tan; Wenzhao Zhong; Yi-Long Wu
Journal:  Lancet Respir Med       Date:  2017-07-19       Impact factor: 30.700

2.  Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.

Authors:  Toyoaki Hida; Hiroshi Nokihara; Masashi Kondo; Young Hak Kim; Koichi Azuma; Takashi Seto; Yuichi Takiguchi; Makoto Nishio; Hiroshige Yoshioka; Fumio Imamura; Katsuyuki Hotta; Satoshi Watanabe; Koichi Goto; Miyako Satouchi; Toshiyuki Kozuki; Takehito Shukuya; Kazuhiko Nakagawa; Tetsuya Mitsudomi; Nobuyuki Yamamoto; Takashi Asakawa; Ryoichi Asabe; Tomohiro Tanaka; Tomohide Tamura
Journal:  Lancet       Date:  2017-05-10       Impact factor: 79.321

3.  Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Authors:  Tony S Mok; Yi-Long Wu; Myung-Ju Ahn; Marina C Garassino; Hye R Kim; Suresh S Ramalingam; Frances A Shepherd; Yong He; Hiroaki Akamatsu; Willemijn S M E Theelen; Chee K Lee; Martin Sebastian; Alison Templeton; Helen Mann; Marcelo Marotti; Serban Ghiorghiu; Vassiliki A Papadimitrakopoulou
Journal:  N Engl J Med       Date:  2016-12-06       Impact factor: 91.245
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.